[{"run_id":"20261014T203208-0851c9a1","observed_at":"2026-10-14 17:50:09.728220+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"0d463f85f3769be119c83e83dc9ce3fb9d5478900dace98b79f646f0acfe6e9c","record_version_id":"9aa4a8730f941012c386d6ed4e559c61923ed09d8e3bfb7b68083862cd7fe3cc","job_id":"enrich-49752a259f17fab0f49665b3","output_id":"06495b4916a89dc388ab11d56ff3ff07c12917046513c651c95302e3c9f4a070","section":"requirements","status":"valid","value_json":"{\"nodes\":[{\"children\":[\"c1\",\"c2\"],\"condition\":null,\"course\":null,\"evidence\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\",\"id\":\"r1\",\"kind\":\"any\"},{\"children\":[],\"condition\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development\",\"course\":null,\"evidence\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development\",\"id\":\"c1\",\"kind\":\"condition\"},{\"children\":[],\"condition\":\"Capstone Certificate in Applied Drug Development\",\"course\":null,\"evidence\":\"Capstone Certificate in Applied Drug Development\",\"id\":\"c2\",\"kind\":\"condition\"}],\"notes\":[],\"root\":\"r1\",\"status\":\"parsed\"}","candidate_json":null,"error":null,"model":"Qwen/Qwen3.8-27B","model_revision":"1d4bf0f2ff6012fd82039f2fa52739d0dd7c60c0","selected_for_release":true},{"run_id":"20261014T203208-0851c9a1","observed_at":"2026-10-14 17:50:09.728220+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"0d463f85f3769be119c83e83dc9ce3fb9d5478900dace98b79f646f0acfe6e9c","record_version_id":"9aa4a8730f941012c386d6ed4e559c61923ed09d8e3bfb7b68083862cd7fe3cc","job_id":"enrich-49752a259f17fab0f49665b3","output_id":"06495b4916a89dc388ab11d56ff3ff07c12917046513c651c95302e3c9f4a070","section":"search_profile","status":"valid","value_json":"{\"activity_tags\":[],\"assumed_background\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"requirements_text\",\"quote\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\"}],\"search_phrases\":[\"drug development process\",\"first-in-human to NDA/BLA\",\"clinical trial phases\",\"biomarkers and companion diagnostics\",\"CMC in clinical trials\",\"small molecule and protein therapeutics\",\"statistical analysis plan\",\"clinical development strategy\"],\"skills_taught\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"official_learning_outcomes\",\"outcome_index\":0,\"quote\":\"Describe the phases of drug development from first-in-human (FIH) studies to NDA/BLA submission and the different functional areas involved.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Describe phases of drug development from FIH to NDA/BLA submission and functional areas.\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"official_learning_outcomes\",\"outcome_index\":1,\"quote\":\"Explain the goals, expectations, and objectives for the different phases of clinical development and describe innovative trial design\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Explain goals and objectives of clinical development phases and describe innovative trial design.\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"official_learning_outcomes\",\"outcome_index\":2,\"quote\":\"Define a biomarker, a companion diagnostic, and a statistical analysis plan (SAP) and describe the important elements of all three.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Define biomarkers, companion diagnostics, and SAPs, describing their important elements.\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"official_learning_outcomes\",\"outcome_index\":3,\"quote\":\"Explain the chemistry, manufacturing, and controls (CMC) activities that take place during clinical phases of drug development and pre-launch.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Explain CMC activities during clinical phases and pre-launch.\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"official_learning_outcomes\",\"outcome_index\":4,\"quote\":\"Apply the knowledge learned throughout the course to address specific drug development challenges and propose novel solutions.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Apply course knowledge to address drug development challenges and propose novel solutions.\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"official_learning_outcomes\",\"outcome_index\":5,\"quote\":\"Evaluate how clinical trial design and execution might differ between different therapeutic areas and between small molecule drugs and protein therapeutics.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Evaluate differences in trial design and execution across therapeutic areas and modalities.\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"official_learning_outcomes\",\"outcome_index\":6,\"quote\":\"Create a clinical development strategy for a specific drug modality and disease combination.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Create a clinical development strategy for a specific drug modality and disease combination.\"}],\"summary\":{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"title\",\"quote\":\"THE DRUG DEVELOPMENT PROCESS FROM FIH TO BLA/NDA\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"},{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA). Phases of clinical development and the role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials. Both small molecule and protein therapeutics will be addressed.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Overview of drug development from first-in-human to NDA/BLA submission, covering clinical phases, biomarkers, companion diagnostics, statistical analysis, CMC, and both small molecule and protein therapeutics.\"},\"topics\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Phases of clinical development and the role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Phases of clinical development, biomarkers, companion diagnostics, statistical analysis, and CMC.\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Both small molecule and protein therapeutics will be addressed.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Small molecule and protein therapeutics.\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"submission of a new drug application (NDA) or biologics license application (BLA)\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"New drug application (NDA) and biologics license application (BLA) submission.\"}]}","candidate_json":null,"error":null,"model":"Qwen/Qwen3.8-27B","model_revision":"1d4bf0f2ff6012fd82039f2fa52739d0dd7c60c0","selected_for_release":true},{"run_id":"20261014T203208-0851c9a1","observed_at":"2026-10-14 17:50:09.728220+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"0d463f85f3769be119c83e83dc9ce3fb9d5478900dace98b79f646f0acfe6e9c","record_version_id":"9aa4a8730f941012c386d6ed4e559c61923ed09d8e3bfb7b68083862cd7fe3cc","job_id":"enrich-49752a259f17fab0f49665b3","output_id":"06495b4916a89dc388ab11d56ff3ff07c12917046513c651c95302e3c9f4a070","section":"student_experience","status":"insufficient_evidence","value_json":"{\"status\":\"insufficient_evidence\",\"themes\":[]}","candidate_json":null,"error":null,"model":"Qwen/Qwen3.8-27B","model_revision":"1d4bf0f2ff6012fd82039f2fa52739d0dd7c60c0","selected_for_release":true},{"run_id":"20261014T203208-0851c9a1","observed_at":"2026-10-14 17:50:09.728220+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"0d463f85f3769be119c83e83dc9ce3fb9d5478900dace98b79f646f0acfe6e9c","record_version_id":"9aa4a8730f941012c386d6ed4e559c61923ed09d8e3bfb7b68083862cd7fe3cc","job_id":"enrich-49752a259f17fab0f49665b3","output_id":"06495b4916a89dc388ab11d56ff3ff07c12917046513c651c95302e3c9f4a070","section":"student_summary","status":"valid","value_json":"{\"context_hash\":\"9c6f3f05dcd7f5f14768be152d767a0b5315e0cb19d16599accb061306669335\",\"course_id\":\"PHMSCI 763\",\"current_instructors\":[{\"instructor_uid\":\"instructor_3aea62525aeb86c5fbe4025b\",\"message\":\"No course-specific reviews available\",\"name\":\"Leslie Dickmann\",\"review_status\":\"no_course_reviews\",\"rmp_instructor_id\":null,\"summary\":[{\"citations\":[{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20261014T203208-0851c9a1\",\"section_number\":2,\"source_course_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"section_grades_latest\",\"term_id\":\"1252\",\"type\":\"grade\"},{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20261014T203208-0851c9a1\",\"section_number\":1,\"source_course_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"section_grades_latest\",\"term_id\":\"1254\",\"type\":\"grade\"},{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20261014T203208-0851c9a1\",\"section_number\":2,\"source_course_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"section_grades_latest\",\"term_id\":\"1254\",\"type\":\"grade\"},{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20261014T203208-0851c9a1\",\"section_number\":1,\"source_course_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"section_grades_latest\",\"term_id\":\"1264\",\"type\":\"grade\"},{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20261014T203208-0851c9a1\",\"section_number\":2,\"source_course_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"section_grades_latest\",\"term_id\":\"1264\",\"type\":\"grade\"}],\"text\":\"Recent recorded grades — Fall 2024: 3.89 GPA, 100.0% A/AB (n=9 letter grades); Spring 2025: 3.75 GPA, 92.9% A/AB (n=28 letter grades); Spring 2026: 3.93 GPA, 100.0% A/AB (n=27 letter grades).\"}]}],\"difficulty_workload\":[],\"errors\":[],\"historical_context\":[],\"message\":\"No course-specific reviews available\",\"offered\":true,\"profile_hash\":\"3f5110430805ccdd533c0c072df62d68a8a5f5441c4530bbdb15d419a199a09c\",\"quick_take\":[{\"citations\":[{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20261014T203208-0851c9a1\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"grades_latest\",\"term_id\":\"1252\",\"type\":\"grade\"},{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20261014T203208-0851c9a1\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"grades_latest\",\"term_id\":\"1254\",\"type\":\"grade\"},{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20261014T203208-0851c9a1\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"grades_latest\",\"term_id\":\"1264\",\"type\":\"grade\"}],\"text\":\"Recent recorded grades — Fall 2024: 3.89 GPA, 100.0% A/AB (n=9 letter grades); Spring 2025: 3.75 GPA, 92.9% A/AB (n=28 letter grades); Spring 2026: 3.93 GPA, 100.0% A/AB (n=27 letter grades).\"}],\"student_experience\":[],\"task_hash\":\"9dea82ef7f2113a5605c1c6030c4f9b19967eb742cc93a78268fb92357d29f5c\",\"teaching_history\":[{\"citations\":[{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20261014T203208-0851c9a1\",\"section_number\":1,\"source_course_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"section_grades_latest\",\"term_id\":\"1244\",\"type\":\"grade\"},{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20261014T203208-0851c9a1\",\"section_number\":2,\"source_course_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"section_grades_latest\",\"term_id\":\"1244\",\"type\":\"grade\"},{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20261014T203208-0851c9a1\",\"section_number\":1,\"source_course_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"section_grades_latest\",\"term_id\":\"1252\",\"type\":\"grade\"},{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20261014T203208-0851c9a1\",\"section_number\":2,\"source_course_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"section_grades_latest\",\"term_id\":\"1252\",\"type\":\"grade\"},{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20261014T203208-0851c9a1\",\"section_number\":1,\"source_course_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"section_grades_latest\",\"term_id\":\"1254\",\"type\":\"grade\"},{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20261014T203208-0851c9a1\",\"section_number\":2,\"source_course_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"section_grades_latest\",\"term_id\":\"1254\",\"type\":\"grade\"},{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20261014T203208-0851c9a1\",\"section_number\":1,\"source_course_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"section_grades_latest\",\"term_id\":\"1264\",\"type\":\"grade\"},{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20261014T203208-0851c9a1\",\"section_number\":2,\"source_course_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"section_grades_latest\",\"term_id\":\"1264\",\"type\":\"grade\"}],\"text\":\"LESLIE DICKMANN is recorded teaching in Spring 2024, Fall 2024, Spring 2025, Spring 2026. Recorded history may be incomplete and does not establish a future schedule.\"}],\"term_id\":\"1274\",\"term_name\":\"2027 Sprng\",\"version\":3}","candidate_json":null,"error":null,"model":"Qwen/Qwen3.8-27B","model_revision":"1d4bf0f2ff6012fd82039f2fa52739d0dd7c60c0","selected_for_release":true},{"run_id":"20260906T231458-5fdd2fff","observed_at":"2026-09-06 23:14:58.172943+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-5291a20b802b9bbbe22b24cb","output_id":"2c00c555958f8b6113d3b21aa005e8b4534631005fa93e929a18d717b42dabf8","section":"requirements","status":"invalid","value_json":null,"candidate_json":"{\"nodes\":[{\"children\":[],\"condition\":null,\"course\":null,\"evidence\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\",\"id\":\"n0\",\"kind\":\"any\"}],\"notes\":[],\"root\":\"n0\",\"status\":\"parsed\"}","error":"Boolean groups require at least two children","model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260906T231458-5fdd2fff","observed_at":"2026-09-06 23:14:58.172943+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-5291a20b802b9bbbe22b24cb","output_id":"2c00c555958f8b6113d3b21aa005e8b4534631005fa93e929a18d717b42dabf8","section":"search_profile","status":"valid","value_json":"{\"assumed_background\":[],\"search_phrases\":[\"drug development process\",\"clinical trials phases\",\"biomarkers diagnostics\",\"CMC clinical trials\",\"small molecule protein therapeutics\",\"NDA BLA submission\"],\"skills_taught\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA)\"}],\"text\":\"Understanding the end-to-end drug development lifecycle from initial human trials to regulatory submission\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Phases of clinical development and the role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials\"}],\"text\":\"Analyzing the roles of biomarkers, diagnostics, statistics, and CMC within clinical trial phases\"}],\"summary\":{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"title\",\"quote\":\"THE DRUG DEVELOPMENT PROCESS FROM FIH TO BLA/NDA\"},{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA)\"}],\"text\":\"PHMSCI 763 covers the drug development process from first-in-human trials to NDA/BLA submission, addressing clinical phases, biomarkers, and therapeutics.\"},\"topics\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Phases of clinical development\"}],\"text\":\"Phases of clinical development\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials\"}],\"text\":\"Biomarkers, companion diagnostics, statistical analysis, and CMC\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Both small molecule and protein therapeutics will be addressed\"}],\"text\":\"Small molecule and protein therapeutics\"}]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260906T231458-5fdd2fff","observed_at":"2026-09-06 23:14:58.172943+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-5291a20b802b9bbbe22b24cb","output_id":"2c00c555958f8b6113d3b21aa005e8b4534631005fa93e929a18d717b42dabf8","section":"student_experience","status":"insufficient_evidence","value_json":"{\"status\":\"insufficient_evidence\",\"themes\":[]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-5590a4969e0a630fe46a86e8","output_id":"c16f06e25019cc6c4d774676ebeec9760eeac2cff9cd0d061a55123eefbf3a12","section":"requirements","status":"valid","value_json":"{\"nodes\":[{\"children\":[],\"condition\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\",\"course\":null,\"evidence\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\",\"id\":\"n0\",\"kind\":\"condition\"}],\"notes\":[],\"root\":\"n0\",\"status\":\"parsed\"}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-5590a4969e0a630fe46a86e8","output_id":"c16f06e25019cc6c4d774676ebeec9760eeac2cff9cd0d061a55123eefbf3a12","section":"search_profile","status":"valid","value_json":"{\"assumed_background\":[],\"search_phrases\":[\"drug development process\",\"clinical trials phases\",\"biomarkers diagnostics\",\"CMC clinical trials\",\"small molecule protein therapeutics\",\"NDA BLA submission\"],\"skills_taught\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA)\"}],\"text\":\"Understanding the end-to-end drug development lifecycle from initial human trials to regulatory submission\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Phases of clinical development and the role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials\"}],\"text\":\"Analyzing the roles of biomarkers, diagnostics, statistics, and CMC within clinical trial phases\"}],\"summary\":{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"title\",\"quote\":\"THE DRUG DEVELOPMENT PROCESS FROM FIH TO BLA/NDA\"},{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA)\"}],\"text\":\"PHMSCI 763 covers the drug development process from first-in-human trials to NDA/BLA submission, addressing clinical phases, biomarkers, and therapeutics.\"},\"topics\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Phases of clinical development\"}],\"text\":\"Phases of clinical development\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials\"}],\"text\":\"Biomarkers, companion diagnostics, statistical analysis, and CMC\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Both small molecule and protein therapeutics will be addressed\"}],\"text\":\"Small molecule and protein therapeutics\"}]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-5590a4969e0a630fe46a86e8","output_id":"c16f06e25019cc6c4d774676ebeec9760eeac2cff9cd0d061a55123eefbf3a12","section":"student_experience","status":"insufficient_evidence","value_json":"{\"status\":\"insufficient_evidence\",\"themes\":[]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20261014T203208-0851c9a1","observed_at":"2026-10-14 17:50:09.728220+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"0d463f85f3769be119c83e83dc9ce3fb9d5478900dace98b79f646f0acfe6e9c","record_version_id":"9aa4a8730f941012c386d6ed4e559c61923ed09d8e3bfb7b68083862cd7fe3cc","job_id":"enrich-6556a505c10f448d98d02466","output_id":"1446d69a285e8c14fb5d08f39f23e12b0341d03ede3dc2b5b266a7f0d0df68bd","section":"requirements","status":"valid","value_json":"{\"nodes\":[{\"children\":[\"c1\",\"c2\"],\"condition\":null,\"course\":null,\"evidence\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\",\"id\":\"r1\",\"kind\":\"any\"},{\"children\":[],\"condition\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development\",\"course\":null,\"evidence\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development\",\"id\":\"c1\",\"kind\":\"condition\"},{\"children\":[],\"condition\":\"Capstone Certificate in Applied Drug Development\",\"course\":null,\"evidence\":\"Capstone Certificate in Applied Drug Development\",\"id\":\"c2\",\"kind\":\"condition\"}],\"notes\":[],\"root\":\"r1\",\"status\":\"parsed\"}","candidate_json":null,"error":null,"model":"Qwen/Qwen3.8-27B","model_revision":"1d4bf0f2ff6012fd82039f2fa52739d0dd7c60c0","selected_for_release":false},{"run_id":"20261014T203208-0851c9a1","observed_at":"2026-10-14 17:50:09.728220+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"0d463f85f3769be119c83e83dc9ce3fb9d5478900dace98b79f646f0acfe6e9c","record_version_id":"9aa4a8730f941012c386d6ed4e559c61923ed09d8e3bfb7b68083862cd7fe3cc","job_id":"enrich-6556a505c10f448d98d02466","output_id":"1446d69a285e8c14fb5d08f39f23e12b0341d03ede3dc2b5b266a7f0d0df68bd","section":"search_profile","status":"valid","value_json":"{\"activity_tags\":[],\"assumed_background\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"requirements_text\",\"quote\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\"}],\"search_phrases\":[\"drug development process\",\"first-in-human to NDA/BLA\",\"clinical trial phases\",\"biomarkers and companion diagnostics\",\"CMC in clinical trials\",\"small molecule and protein therapeutics\",\"statistical analysis plan\",\"clinical development strategy\"],\"skills_taught\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"official_learning_outcomes\",\"outcome_index\":0,\"quote\":\"Describe the phases of drug development from first-in-human (FIH) studies to NDA/BLA submission and the different functional areas involved.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Describe phases of drug development from FIH to NDA/BLA submission and functional areas.\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"official_learning_outcomes\",\"outcome_index\":1,\"quote\":\"Explain the goals, expectations, and objectives for the different phases of clinical development and describe innovative trial design\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Explain goals and objectives of clinical development phases and describe innovative trial design.\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"official_learning_outcomes\",\"outcome_index\":2,\"quote\":\"Define a biomarker, a companion diagnostic, and a statistical analysis plan (SAP) and describe the important elements of all three.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Define biomarkers, companion diagnostics, and SAPs, describing their important elements.\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"official_learning_outcomes\",\"outcome_index\":3,\"quote\":\"Explain the chemistry, manufacturing, and controls (CMC) activities that take place during clinical phases of drug development and pre-launch.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Explain CMC activities during clinical phases and pre-launch.\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"official_learning_outcomes\",\"outcome_index\":4,\"quote\":\"Apply the knowledge learned throughout the course to address specific drug development challenges and propose novel solutions.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Apply course knowledge to address drug development challenges and propose novel solutions.\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"official_learning_outcomes\",\"outcome_index\":5,\"quote\":\"Evaluate how clinical trial design and execution might differ between different therapeutic areas and between small molecule drugs and protein therapeutics.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Evaluate differences in trial design and execution across therapeutic areas and modalities.\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"official_learning_outcomes\",\"outcome_index\":6,\"quote\":\"Create a clinical development strategy for a specific drug modality and disease combination.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Create a clinical development strategy for a specific drug modality and disease combination.\"}],\"summary\":{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"title\",\"quote\":\"THE DRUG DEVELOPMENT PROCESS FROM FIH TO BLA/NDA\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"},{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA). Phases of clinical development and the role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials. Both small molecule and protein therapeutics will be addressed.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Overview of drug development from first-in-human to NDA/BLA submission, covering clinical phases, biomarkers, companion diagnostics, statistical analysis, CMC, and both small molecule and protein therapeutics.\"},\"topics\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Phases of clinical development and the role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Phases of clinical development, biomarkers, companion diagnostics, statistical analysis, and CMC.\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Both small molecule and protein therapeutics will be addressed.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Small molecule and protein therapeutics.\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"submission of a new drug application (NDA) or biologics license application (BLA)\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"New drug application (NDA) and biologics license application (BLA) submission.\"}]}","candidate_json":null,"error":null,"model":"Qwen/Qwen3.8-27B","model_revision":"1d4bf0f2ff6012fd82039f2fa52739d0dd7c60c0","selected_for_release":false},{"run_id":"20261014T203208-0851c9a1","observed_at":"2026-10-14 17:50:09.728220+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"0d463f85f3769be119c83e83dc9ce3fb9d5478900dace98b79f646f0acfe6e9c","record_version_id":"9aa4a8730f941012c386d6ed4e559c61923ed09d8e3bfb7b68083862cd7fe3cc","job_id":"enrich-6556a505c10f448d98d02466","output_id":"1446d69a285e8c14fb5d08f39f23e12b0341d03ede3dc2b5b266a7f0d0df68bd","section":"student_experience","status":"insufficient_evidence","value_json":"{\"status\":\"insufficient_evidence\",\"themes\":[]}","candidate_json":null,"error":null,"model":"Qwen/Qwen3.8-27B","model_revision":"1d4bf0f2ff6012fd82039f2fa52739d0dd7c60c0","selected_for_release":false},{"run_id":"20260906T231458-5fdd2fff","observed_at":"2026-09-06 23:14:58.172943+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-789789da373eecc1ff75f626","output_id":"6474954471aa885be945510330f9ddfbf6407fc22f2e2e3cd82761052b4e05d2","section":"requirements","status":"needs_review","value_json":"{\"nodes\":[{\"children\":[],\"condition\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\",\"course\":null,\"evidence\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\",\"id\":\"n0\",\"kind\":\"condition\"}],\"notes\":[],\"root\":\"n0\",\"status\":\"parsed\"}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260906T231458-5fdd2fff","observed_at":"2026-09-06 23:14:58.172943+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-789789da373eecc1ff75f626","output_id":"6474954471aa885be945510330f9ddfbf6407fc22f2e2e3cd82761052b4e05d2","section":"search_profile","status":"valid","value_json":"{\"assumed_background\":[],\"search_phrases\":[\"drug development process\",\"clinical trials phases\",\"biomarkers diagnostics\",\"CMC clinical trials\",\"small molecule protein therapeutics\",\"NDA BLA submission\"],\"skills_taught\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA)\"}],\"text\":\"Understanding the end-to-end drug development lifecycle from initial human trials to regulatory submission\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Phases of clinical development and the role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials\"}],\"text\":\"Analyzing the roles of biomarkers, diagnostics, statistics, and CMC within clinical trial phases\"}],\"summary\":{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"title\",\"quote\":\"THE DRUG DEVELOPMENT PROCESS FROM FIH TO BLA/NDA\"},{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA)\"}],\"text\":\"PHMSCI 763 covers the drug development process from first-in-human trials to NDA/BLA submission, addressing clinical phases, biomarkers, and therapeutics.\"},\"topics\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Phases of clinical development\"}],\"text\":\"Phases of clinical development\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials\"}],\"text\":\"Biomarkers, companion diagnostics, statistical analysis, and CMC\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Both small molecule and protein therapeutics will be addressed\"}],\"text\":\"Small molecule and protein therapeutics\"}]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260906T231458-5fdd2fff","observed_at":"2026-09-06 23:14:58.172943+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-789789da373eecc1ff75f626","output_id":"6474954471aa885be945510330f9ddfbf6407fc22f2e2e3cd82761052b4e05d2","section":"student_experience","status":"insufficient_evidence","value_json":"{\"status\":\"insufficient_evidence\",\"themes\":[]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-8b774950c2b6adfdc46d1b82","output_id":"d2e417dcf56ac41578787954ca4185d0f53f17dff00d090bdb096d53f031fee1","section":"requirements","status":"valid","value_json":"{\"nodes\":[{\"children\":[],\"condition\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\",\"course\":null,\"evidence\":\"Declared in MS Pharmaceutical Sciences: Applied Drug Development or Capstone Certificate in Applied Drug Development\",\"id\":\"n0\",\"kind\":\"condition\"}],\"notes\":[],\"root\":\"n0\",\"status\":\"parsed\"}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-8b774950c2b6adfdc46d1b82","output_id":"d2e417dcf56ac41578787954ca4185d0f53f17dff00d090bdb096d53f031fee1","section":"search_profile","status":"valid","value_json":"{\"assumed_background\":[],\"search_phrases\":[\"drug development process\",\"clinical trials phases\",\"biomarkers diagnostics\",\"CMC clinical trials\",\"small molecule protein therapeutics\",\"NDA BLA submission\"],\"skills_taught\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA)\"}],\"text\":\"Understanding the end-to-end drug development lifecycle from initial human trials to regulatory submission\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Phases of clinical development and the role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials\"}],\"text\":\"Analyzing the roles of biomarkers, diagnostics, statistics, and CMC within clinical trial phases\"}],\"summary\":{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"title\",\"quote\":\"THE DRUG DEVELOPMENT PROCESS FROM FIH TO BLA/NDA\"},{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Overview of the drug development process from first-in-human (FIH) to submission of a new drug application (NDA) or biologics license application (BLA)\"}],\"text\":\"PHMSCI 763 covers the drug development process from first-in-human trials to NDA/BLA submission, addressing clinical phases, biomarkers, and therapeutics.\"},\"topics\":[{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Phases of clinical development\"}],\"text\":\"Phases of clinical development\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"role of biomarkers, companion diagnostics, statistical analysis, and CMC in clinical trials\"}],\"text\":\"Biomarkers, companion diagnostics, statistical analysis, and CMC\"},{\"evidence\":[{\"course_id\":\"PHMSCI 763\",\"field\":\"description\",\"quote\":\"Both small molecule and protein therapeutics will be addressed\"}],\"text\":\"Small molecule and protein therapeutics\"}]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-8b774950c2b6adfdc46d1b82","output_id":"d2e417dcf56ac41578787954ca4185d0f53f17dff00d090bdb096d53f031fee1","section":"student_experience","status":"insufficient_evidence","value_json":"{\"status\":\"insufficient_evidence\",\"themes\":[]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_b7da72aecf53dbf40a363e61","course_id":"PHMSCI 763","catalog_version_id":"9175f1759595135dffb4d3a74fa30fbc555bdc5afa3f29449dd1c84a8a860282","record_version_id":"ba5f1ea43fbd75baa388ed7fe49ee45cbb5b1fdbcdbd5df71a084fc673984f7c","job_id":"enrich-8b774950c2b6adfdc46d1b82","output_id":"d2e417dcf56ac41578787954ca4185d0f53f17dff00d090bdb096d53f031fee1","section":"student_summary","status":"valid","value_json":"{\"context_hash\":\"98146676635ec80db84182ced9d35014301fbf1d31eadae7d8e49782de53db13\",\"course_id\":\"PHMSCI 763\",\"current_instructors\":[],\"difficulty_workload\":[],\"errors\":[],\"historical_context\":[],\"message\":\"No course-specific reviews available\",\"offered\":false,\"profile_hash\":\"5cb4dabf887cdbcd8c00d5a1312e10828b95c63f30bc3ea76aea199565390d02\",\"quick_take\":[{\"citations\":[{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20260907T155543-ce3781c4\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"grades_latest\",\"term_id\":\"1252\",\"type\":\"grade\"},{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20260907T155543-ce3781c4\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"grades_latest\",\"term_id\":\"1254\",\"type\":\"grade\"},{\"course_id\":\"PHMSCI 763\",\"run_id\":\"20260907T155543-ce3781c4\",\"source_record\":{\"entity_id\":\"0c4e1947-79bd-3097-93c6-dd701cfd65fb\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"grades_latest\",\"term_id\":\"1264\",\"type\":\"grade\"}],\"text\":\"Recent recorded grades — Fall 2024: 3.89 GPA, 100.0% A/AB (n=9 letter grades); Spring 2025: 3.75 GPA, 92.9% A/AB (n=28 letter grades); Spring 2026: 3.93 GPA, 100.0% A/AB (n=27 letter grades).\"}],\"student_experience\":[],\"task_hash\":\"74fb0997943e888960bbc9e47db8c4fd12e4292d55c20509d8d89db6a9910f68\",\"teaching_history\":[],\"term_id\":\"1272\",\"term_name\":\"2026 Fall\",\"version\":2}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false}]